Journal
ACS NANO
Volume 9, Issue 1, Pages 62-70Publisher
AMER CHEMICAL SOC
DOI: 10.1021/nn5056282
Keywords
cancer diagnosis; circulating tumor cells; nanostructured materials; thermoresponsive polymer; non-small cell lung cancer
Categories
Funding
- National Institutes of Health [R21-CA151159, R33-CA157396, P50-CA92131, R33-CA174562, PO1-CA168585]
- RIKEN
- Academia Sinica
- Academia Sinica Research Project on Nanoscience and Technology
- National Natural Science Foundation of China [30900650/H1615, 81372501/H1615]
- NATIONAL CANCER INSTITUTE [R21CA151159, U01CA198900, P50CA092131, R33CA157396, P01CA168585, R33CA174562] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Unlike tumor biopsies that can be constrained by problems such as sampling bias, circulating tumor cells (CTCs) are regarded as the liquid biopsy of the tumor, providing convenient access to all disease sites, including primary tumor and fatal metastases. Although enumerating CTCs is of prognostic significance in solid tumors, it is conceivable that performing molecular and functional analyses on CTCs will reveal much significant insight into tumor biology to guide proper therapeutic intervention. We developed the Thermoresponsive NanoVelcro CTC purification system that can be digitally programmed to achieve an optimal performance for purifying CTCs from non-small cell lung cancer (NSCLC) patients. The performance of this unique CTC purification system was optimized by systematically modulating surface chemistry, flow rates, and heating/cooling cycles. By applying a physiologically endurable stimulation (i.e., temperature between 4 and 37 degrees C), the mild operational parameters allow minimum disruption to CTCs viability and molecular integrity. Subsequently, we were able to successfully demonstrate culture expansion and mutational analysis of the CTCs purified by this CTC purification system. Most excitingly, we adopted the combined use of the Thermoresponsive NanoVelcro system with downstream mutational analysis to monitor the disease evolution of an index NSCLC patient, highlighting its translational value in managing NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available